Germany | Bayern

Zurück zur Suche

Internationale Partnersuche

Innovation & Technologie Angebot

New ligands for targeting of S1P receptors for in vivo imaging and treatment of diseases.

Country of Origin: Germany
Reference Number: TODE20170825001
Publication Date: 30 August 2017

Summary

A technology transfer office in Germany (Bavaria) represents a known German university. Scientists of its institute have invented novel radioactive and fluorescent compounds, which can be used as radiotracers/markers for imaging techniques and diagnostic tools for various diseases or disorders such as inflammation, pain, autoimmune diseases and cardiovascular diseases which are related to sphin-gosine-1-phosphate (S1P) receptors. They are looking for partners to enter into a license agreement.

Description

The technology transfer office in Germany, which represents a known German university, has invented novel compounds in the field of diseases or disorders related to sphingosine-1-phosphate (S1P), which is a signaling sphingolipid. It is also referred to as a bioactive lipid mediator. 
Although S1P is of importance in the entire human body, it is a major regulator of the vascular and immune system and regulates angiogenesis, vascular stability and permeability. In addition, it might be relevant in the skin.
Sphingosine 1-phosphate receptors (S1PRs) are G protein-coupled receptors expressed by many cell types, including immune and neural cells. These receptors are promising targets for immunomodulatory and possibly neuro-modulatory therapies.

The present invention relates to novel compounds, in particular, novel radioactive and fluorescent compounds, their preparation, and the use of such novel radioactive or fluorescent compounds as radiotracers/markers for imaging techniques and diagnostic tools in the field of diseases or disorders related to S1P receptors in particular in diseases which are connected to the regulatory function of sphingosine-1-phosphate (S1P) and its analogues, such as inflammation, pain, autoimmune diseases and cardiovascular diseases.
They want to enter into a license agreement.

Advantages and Innovations

Advantages of the invention
When the compounds of the invention are labelled or bearing dyes, they have a clear advantage, as they can be applied in a lower dose for diagnostic purposes that will not interfere with any simultaneous treatments with drugs targeting the same receptors. It is possible to administrate the compounds of the invention for imaging to patients treated simultaneously with such drugs as only amounts of the compound of the invention will be necessary. The compounds of the invention will not compete for biological activity with such drugs and hence will not need any adjustment of the therapy with such drugs.

New aspects of the invention
The novel compounds can be used as imaging agents for a human disease (pain, immunological, inflammatory, neurological, cardiovascular, rheumatic, autoimmune, allergic, infectious, haematological, degenerative, oncological, ophthalmological or metabolic disease) in which S1P and its receptors play a role. The novel compounds can be used in positron emission tomography (PET), single photon emission computed tomography (SEPCT) or in fluorescence imaging.

Stage Of Development

Under development/lab tested

Requested partner

They are looking for a licensee who is able to produce the novel compounds provided in this offer and market the products.

Kooperationsanfrage stellen